%0 Journal Article
%T A Randomized Controlled Study of Chemotherapy:  Etoposide Combined with Oxaliplatin or Cisplatin Regimens in the Treatment  of Extensive-stage Small Cell Lung Cancer in Elderly Patients
%A Dan PU
%A Mei HOU
%A Zhixi LI
%A Xiaomei ZENG
%J Chinese Journal of Lung Cancer
%D 2013
%I Chinese Anti-Cancer Association; Chinese Antituberculosis Association
%R 10.3779/j.issn.1009-3419.2013.01.04
%X Background and objective Etoposide combined cisplatin (EP) is the most commonly-used first-line treatment combination chemotherapy regimen in the treatment of extensive-stage small cell lung cancer (SCLC), The side-effects of cisplatin, such as nausea and vomiting, influence patients¡¯ quality of life. This study aims to compare the efficacy and toxicities between etoposide plus oxaliplatin (EO) and etoposide plus cisplatin (EP) regimens as first-line chemotherapy for elderly patients with SCLC. Methods Seventy-one old, extensive-stage SCLC patients, who had not received anti-tumor treatment, were randomly divided into two groups, namely, EO group (etoposide: 80 mg/m2 d1-5+oxaliplatin; 130 mg/m2 d1; repeated every 21 days) and EP group (etoposide: 80 mg/m2 d1-5+cisplatin; 25 mg/m2 d1-3; repeated every 21 days). Efficacy and toxicities were evaluated after 2 or more cycles. Results No statistical differences were observed between the EO and EP groups in the response rate (55.9% vs 54.3%, P=0.894), disease control rate (82.4% vs 77.1%, P=0.591), median progression free survival (5.5 months vs 4.7 months, P=0.638), and median survival time (10.5 months vs 9.1 months, P=0.862). In terms of toxicities, the incidence of nausea/vomiting in the EO group was significantly lower than that in the EP group (65.7% vs 97.2%, P=0.001), but the neurotoxicity of grade 1-2 in the EO group was more significant (74.3% vs 11.1%, P<0.001). Conclusion The clinical efficiency of EO and EP regimens is similar to the first-line chemotherapy for extensive-stage SCLC in elderly patients. However, the tolerance of EO regimens is better than that in the EP regiments.
%K Etoposide
%K Oxaliplatin
%K Cisplatin
%K Small cell lung cancer
%K The elderly
%U http://dx.doi.org/10.3779/j.issn.1009-3419.2013.01.04